Viridian Therapeutics Q4 2024 Earnings Report
Key Takeaways
Viridian Therapeutics reported positive topline phase 3 data for veligrotug in patients with active and chronic thyroid eye disease (TED), advanced its REVEAL-1 and REVEAL-2 phase 3 clinical trials for VRDN-003, and anticipates proof-of-concept clinical data for VRDN-006 in Q3 2025. The company's cash position was strong at $717.6 million as of December 31, 2024, providing a cash runway into the second half of 2027.
Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED).
REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026.
Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn).
Strong cash position of $717.6 million as of December 31, 2024; provides cash runway into the second half of 2027.
Viridian Therapeutics
Viridian Therapeutics
Viridian Therapeutics Revenue by Segment
Forward Guidance
Viridian anticipates topline data from both REVEAL-1 and REVEAL-2 in the first half of 2026, with a BLA submission planned by year-end 2026. Viridian expects data from the phase 1 clinical trial in Q3 2025, including proof-of-concept IgG reduction data in healthy volunteers.
Positive Outlook
- BLA submission is on track for the second half of 2025, with an MAA submission to the European Medicines Agency expected in the first half of 2026.
- Patient enrollment and dosing continues in both phase 3 clinical trials.
- Topline Data On Track for 1H 2026: Viridian anticipates topline data from both REVEAL-1 and REVEAL-2 in the first half of 2026, with a BLA submission planned by year-end 2026.
- Viridian expects data from the phase 1 clinical trial in Q3 2025, including proof-of-concept IgG reduction data in healthy volunteers.
- Additional Preclinical Data Expected in 2025: Non-human primate (NHP) studies are ongoing to generate additional data for VRDN-008.